Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Martina Properzi, Paola Magro, Francesco Castelli & Eugenia Quiros-Roldan. (2018) Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Review of Anti-infective Therapy 16:12, pages 877-887.
Read now
Read now
Onyema Ogbuagu. (2016) Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review of Anti-infective Therapy 14:12, pages 1113-1126.
Read now
Read now
Articles from other publishers (17)
Kui Liu, Zhen Hao, Hao Zheng, Haojie Wang, Luying Zhang, Minghui Yan, Reyisha Tuerhong, Yuling Zhou, Yan Wang, Tao Pang & Lei Shi. (2023) Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation. Thrombosis Research 229, pages 53-68.
Crossref
Crossref
Supphachoke Khemla, Atibordee Meesing, Wantin Sribenjalux & Ploenchan Chetchotisakd. (2023) Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. Drug Target Insights 17, pages 49-53.
Crossref
Crossref
Carmen Busca Arenzana, Juan González-García, Ana Blas-García, Juan V. Esplugues, Antonio Olveira Martín & Maria Luisa Montes Ramírez. (2023) Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. Enfermedades infecciosas y microbiologia clinica (English ed.).
Crossref
Crossref
Carmen Busca Arenzana, Juan González-García, Ana Blas-García, Juan V. Esplugues, Antonio Olveira Martín & Maria Luisa Montes Ramírez. (2022) Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. Enfermedades Infecciosas y Microbiología Clínica.
Crossref
Crossref
Federico Lucantoni, Ana M. Benedicto, Aleksandra Gruevska, Ángela B. Moragrega, Isabel Fuster-Martínez, Juan V. Esplugues, Ana Blas-García & Nadezda Apostolova. (2022) Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less. Cell Death & Disease 13:4.
Crossref
Crossref
Ana M. Benedicto, Isabel Fuster-Martínez, Joan Tosca, Juan V. Esplugues, Ana Blas-García & Nadezda Apostolova. (2021) NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. Cells 10:7, pages 1687.
Crossref
Crossref
. (2021) Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS 35:6, pages 869-882.
Crossref
Crossref
Carlos D. Malvestutto & Judith A. Aberg. 2021. Therapeutic Lipidology. Therapeutic Lipidology
431
466
.
Edidiong Nnamso Akang, Olufunke O Dosumu, Ini-ibehe Essien Okoko, Oluwatomisin Faniyan, Ademola A Oremosu & Alani Sulaimon Akanmu. (2020) Microscopic and biochemical changes on liver and kidney of Wistar rats on combination antiretroviral therapy: the impact of naringenin and quercetin. Toxicology Research 9:5, pages 601-608.
Crossref
Crossref
Alberto Martí-Rodrigo, Fernando Alegre, Ángela B Moragrega, Francisco García-García, Pablo Martí-Rodrigo, Anabel Fernández-Iglesias, Jordi Gracia-Sancho, Nadezda Apostolova, Juan V Esplugues & Ana Blas-García. (2020) Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut 69:5, pages 920-932.
Crossref
Crossref
Adrian Curran, Anna Rull, Jordi Navarro, Judit Vidal-González, Mario Martin-Castillo, Joaquin Burgos, Vicenç Falcó, Esteban Ribera, Ariadna Torrella, Bibiana Planas, Joaquim Peraire & Manuel Crespo. (2020) Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. Journal of Clinical Medicine 9:5, pages 1246.
Crossref
Crossref
Porkaew Petchkum, Somnuek Sungkanuparph, Sasisopin Kiertiburanakul & Angsana Phuphuakrat. (2019) Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial. Open Forum Infectious Diseases 6:4.
Crossref
Crossref
Willem Daniel Francois Venter, Andrew Kambugu, Matthew F. Chersich, Stephen Becker, Andrew Hill, Natasha Arulappan, Michelle Moorhouse, Mohammed Majam, Godspower Akpomiemie, Simiso Sokhela, Selvamuthu Poongulali, Charles Feldman, Chris Duncombe, David H. Brown Ripin, Alinda Vos & Nagalingeswaran Kumarasamy. (2019) Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes 80:2, pages 224-233.
Crossref
Crossref
D Hagins, C Orkin, ES Daar, A Mills, C Brinson, E DeJesus, FA Post, J Morales-Ramirez, M Thompson, O Osiyemi, B Rashbaum, H-J Stellbrink, C Martorell, H Liu, Y-P Liu, D Porter, SE Collins, D SenGupta & M Das. (2018) Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Medicine 19:10, pages 724-733.
Crossref
Crossref
A Ocampo, P Domingo, P Fernández, J Diz, J R Barberá, M A Sepúlveda, X Salgado, M Rodriguez, J Santos, M Yzusqui, M I Mayorga, J F Lorenzo, A Bahamonde, P Bachiller, E Martínez, N Rozas, C Torres, A Muñoz, A Casado & D Podzamczer. (2018) Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. Journal of Antimicrobial Chemotherapy 73:8, pages 2171-2176.
Crossref
Crossref
Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Torsak Bunupuradah, Tim R Cressey, Angela Colbers, David M Burger, Wanatpreeya Phongsamart, Thanyawee Puthanakit & Chitsanu Pancharoen. (2017) Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. Antiviral Therapy 23:3, pages 259-265.
Crossref
Crossref
Elke Wynberg, Eleri Williams, Gareth Tudor-Williams, Hermione Lyall & Caroline Foster. (2017) Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?. Clinical Drug Investigation 38:3, pages 231-238.
Crossref
Crossref